...from FDA to treat AD. Pfizer Inc. (NYSE:PFE) had licensed azeliragon from vTv predecessor company TransTech...

...vTv (formerly TransTech Pharma LLC ) began the double-blind, placebo-controlled, North American Phase III trial to evaluate 5...

...rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech...
...over expressed in many cancers and has been linked to more aggressive and invasive tumors. TransTech Pharma LLC...

...trial by year end. TTP488 has Fast Track designation In the U.S. to treat AD. TransTech...
...modulate RAGE. TransTech said Pfizer terminated the deal in 3Q11 (see BioCentury, Sept. 25, 2006). TransTech Pharma LLC...

...Holcombe to president of TransTech and affiliate company High Point Pharmaceuticals LLC from SVP of TransTech...
...remaining CFO of TransTech; he succeeds Adnan Mjalli, who resigned as president and CEO of TransTech...

...companies have programs in Phase II trials that target PTP-1B to treat Type II diabetes. TransTech...
...Jupiter, Fla. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Targanox Inc. , Cambridge, Mass. TransTech...

...PF-04937319 Phase II Roche HMS5552 (formerly RO5305552) Phase I Teijin Pharma Ltd. TMG-123 Phase I TransTech...

...plc have a small molecule CRHR1 antagonist in Phase II testing for various neurological indications. TransTech...
...Jolla, Calif. Shanghai Institute of Materia Medica , Shanghai, China Stanford University , Stanford, Calif. TransTech...

...of <=6.5% in 85% of patients. No patients in the placebo group achieved HbA1c <=6.5%. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...
...BioCentury, June 14, 2010). TransTech said it plans to identify another partner for the program. TransTech...

...NYSE:FRX) conducted the trial, which enrolled 128 Type II diabetics on stable doses of metformin. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...